U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138222) titled 'IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma' on July 21.
Brief Summary: This study aims to capture information regarding the effect of immune checkpoint inhibitor (ICI) treatment for melanoma on reproductive organ function and sex hormone levels.
You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with melanoma (Stage II, III or IV) and you are planning to receive ICI treatment. Additional criteria will apply dependent upon your biological sex characteristics.
All participants who choose to enroll in this study will be asked to complete...